Pre-made Itolizumab benchmark antibody ( Whole mAb, anti-CD6/TP120 therapeutic antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Itolizumab biosimilar, Whole Mab: Anti-CD6/TP120 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Itolizumab (INN, trade name Alzumab) is a “first in class” humanized IgG1 monoclonal antibody developed by Biocon and the Center of Molecular Immunology (CIM), Havana.
| Products Name (INN Index) | Pre-Made Itolizumab biosimilar, Whole Mab: Anti-CD6/TP120 therapeutic antibody |
|---|---|
| INN Name | Itolizumab |
| Target | CD6 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2010 |
| Year Recommended | 2011 |
| Companies | Center of Molecular Immunology,Biocon,Biotech Pharmaceutical,Equillium |
| Conditions Approved | Plaque psoriasis |
| Conditions Active | Graft-versus-host disease,Cytokine release syndrome,COVID-19,Asthma,Lupus nephritis |
| Conditions Discontinued | Autoimmune disorders,Multiple sclerosis,Psoriasis,Rheumatoid arthritis |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | CD6 |
| Package |
